Epcoritamab + R-GemOx for Diffuse Large B-Cell Lymphoma

This trial tests a new combination treatment for individuals with diffuse large B-cell lymphoma (DLBCL) that has returned or resisted previous treatments. The treatment combines epcoritamab, a drug that helps the immune system attack cancer, with three other drugs commonly used for this lymphoma type: gemcitabine, oxaliplatin, and rituximab. The researchers aim to determine if this combination can better prepare patients for a stem cell transplant by reducing their cancer. This trial may suit those whose DLBCL has recurred or remains difficult to treat after at least one round of chemoimmunotherapy. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications. However, it does mention that active medications known to decrease T-cell numbers or activity, or other immunosuppressive medications, should not be used within a certain period before starting the trial. It's best to discuss your specific medications with the trial team.

Research has shown that combining epcoritamab with gemcitabine and oxaliplatin is generally safe and well-tolerated by patients with diffuse large B-cell lymphoma (DLBCL). Studies indicate that many patients experience tumor reduction or remission with this treatment, which is also linked to longer survival times. Although all treatments can have side effects, evidence suggests that most patients can manage this combination. Patients should always discuss potential side effects and concerns with their healthcare provider.¹²³⁴⁵

Researchers are excited about Epcoritamab combined with R-GemOx for treating Diffuse Large B-Cell Lymphoma because it introduces a novel approach compared to traditional treatments like R-CHOP. Epcoritamab is a bispecific antibody, meaning it can simultaneously engage both the cancer cells and the immune system, potentially enhancing the body's ability to fight the cancer. Additionally, Epcoritamab is administered subcutaneously, which might offer a more convenient and less invasive option compared to intravenous treatments. This combination aims to optimize both attack on the cancer and patient comfort, offering new hope for those with this challenging condition.

Research has shown that combining epcoritamab with gemcitabine and oxaliplatin (Epcor+GemOx) may effectively treat diffuse large B-cell lymphoma (DLBCL) that is difficult to manage. In this trial, participants will receive Epcor+GemOx, which previous studies have found to improve response rates and survival outcomes compared to the usual treatment with rituximab, gemcitabine, and oxaliplatin (R-GemOx). Epcoritamab is a special type of antibody that helps the immune system target and destroy cancer cells. Gemcitabine and oxaliplatin are chemotherapy drugs that damage the DNA of cancer cells. This combination might benefit patients whose cancer has returned or hasn't responded to other treatments.¹²³⁵⁶